{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Viread+%28tenofovir+DF%29",
    "query": {
      "intervention": "Viread (tenofovir DF)"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 518,
    "total_pages": 52,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Viread+%28tenofovir+DF%29&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-10-01T19:23:16.228Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00035932",
      "title": "Atazanavir (BMS-232632) in Combination With Ritonavir or Saquinavir, and Lopinavir/Ritonavir, Each With Tenofovir and a Nucleoside in Subjects With HIV",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Atazanavir + ritonavir + tenofovir + nucleoside",
          "type": "DRUG"
        },
        {
          "name": "Atazanavir + saquinavir + tenofovir + nucleoside",
          "type": "DRUG"
        },
        {
          "name": "Lopinavir/ritonavir + tenofovir + nucleoside",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": 571,
      "start_date": "2001-11",
      "completion_date": "2009-03",
      "has_results": true,
      "last_update_posted_date": "2010-12-24",
      "last_synced_at": "2026-10-01T19:23:16.228Z",
      "location_count": 29,
      "location_summary": "San Francisco, California • Torrance, California • Boulder, Colorado + 23 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Boulder",
          "state": "Colorado"
        },
        {
          "city": "Altamonte Springs",
          "state": "Florida"
        },
        {
          "city": "Fort Lauderdale",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00035932"
    },
    {
      "nct_id": "NCT01721109",
      "title": "Pharmacokinetics, Safety, and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single Tablet Regimen (STR) in Adolescents",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Acquired Immunodeficiency Syndrome",
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "EVG/COBI/FTC/TDF",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "12 Years to 17 Years"
      },
      "enrollment_count": 50,
      "start_date": "2012-12-06",
      "completion_date": "2018-01-29",
      "has_results": true,
      "last_update_posted_date": "2018-08-17",
      "last_synced_at": "2026-10-01T19:23:16.228Z",
      "location_count": 7,
      "location_summary": "Oakland, California • Tampa, Florida • Chicago, Illinois + 4 more",
      "locations": [
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "The Bronx",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01721109"
    },
    {
      "nct_id": "NCT05755204",
      "title": "A Pharmacist-run PrEP Program for Women",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "HIV Prevention"
      ],
      "interventions": [
        {
          "name": "LA-CAB",
          "type": "DRUG"
        },
        {
          "name": "TDF/FTC",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Orlando Immunology Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 65 Years · Female only"
      },
      "enrollment_count": 2,
      "start_date": "2023-06-21",
      "completion_date": "2024-10-15",
      "has_results": false,
      "last_update_posted_date": "2025-02-14",
      "last_synced_at": "2026-10-01T19:23:16.228Z",
      "location_count": 1,
      "location_summary": "Orlando, Florida",
      "locations": [
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05755204"
    },
    {
      "nct_id": "NCT00033163",
      "title": "A Comparison of Adefovir and Tenofovir for the Treatment of Lamivudine-Resistant Hepatitis B Virus in People With HIV",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HIV Infections",
        "Hepatitis B"
      ],
      "interventions": [
        {
          "name": "Adefovir dipivoxil",
          "type": "DRUG"
        },
        {
          "name": "Tenofovir disoproxil fumarate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 90,
      "start_date": null,
      "completion_date": "2005-05",
      "has_results": false,
      "last_update_posted_date": "2021-11-01",
      "last_synced_at": "2026-10-01T19:23:16.228Z",
      "location_count": 15,
      "location_summary": "Sacramento, California • San Francisco, California • Aurora, Colorado + 7 more",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00033163"
    },
    {
      "nct_id": "NCT04040075",
      "title": "Testing the Safety and Efficacy of Commercial Drug Biktarvy in Subjects Known to Have the 184 Resistance Mutation to a Component in Biktarvy",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "HIV-1-infection"
      ],
      "interventions": [
        {
          "name": "Biktarvy Tab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Southampton Healthcare, Inc.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2019-07-01",
      "completion_date": "2022-07-08",
      "has_results": false,
      "last_update_posted_date": "2023-01-05",
      "last_synced_at": "2026-10-01T19:23:16.228Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04040075"
    },
    {
      "nct_id": "NCT00224445",
      "title": "Boosted Atazanavir and Truvada Given Once-Daily - BATON Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Truvada",
          "type": "DRUG"
        },
        {
          "name": "Atazanavir",
          "type": "DRUG"
        },
        {
          "name": "Ritonavir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2005-09",
      "completion_date": "2007-01",
      "has_results": false,
      "last_update_posted_date": "2013-01-10",
      "last_synced_at": "2026-10-01T19:23:16.228Z",
      "location_count": 1,
      "location_summary": "Foster City, California",
      "locations": [
        {
          "city": "Foster City",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00224445"
    },
    {
      "nct_id": "NCT04692077",
      "title": "Safety, Tolerability and Acceptability of Long-Acting Cabotegravir (CAB LA) for the Prevention of HIV Among Adolescent Males",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Cabotegravir (CAB) tablet",
          "type": "DRUG"
        },
        {
          "name": "CAB LA",
          "type": "DRUG"
        },
        {
          "name": "Tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) tablet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "17 Years",
        "sex": "MALE",
        "summary": "Up to 17 Years · Male only"
      },
      "enrollment_count": 9,
      "start_date": "2020-02-19",
      "completion_date": "2023-07-07",
      "has_results": true,
      "last_update_posted_date": "2025-05-20",
      "last_synced_at": "2026-10-01T19:23:16.228Z",
      "location_count": 4,
      "location_summary": "Aurora, Colorado • Chicago, Illinois • Boston, Massachusetts + 1 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04692077"
    },
    {
      "nct_id": "NCT04563962",
      "title": "Contingency Management for PrEP Adherence and/or Methamphetamine Use",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Methamphetamine-dependence",
        "HIV-1-infection"
      ],
      "interventions": [
        {
          "name": "Contingency Management-ART",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Contingency Management-Methamphetamine",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of California, Los Angeles",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 20,
      "start_date": "2021-03-15",
      "completion_date": "2021-08-31",
      "has_results": false,
      "last_update_posted_date": "2021-09-29",
      "last_synced_at": "2026-10-01T19:23:16.228Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04563962"
    },
    {
      "nct_id": "NCT02750540",
      "title": "Optimization of a Tenofovir Enema for HIV Prevention",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Prevention"
      ],
      "interventions": [
        {
          "name": "Tenofovir enema",
          "type": "DRUG"
        },
        {
          "name": "Saline enema",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Johns Hopkins University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 21,
      "start_date": "2016-10",
      "completion_date": "2019-05",
      "has_results": false,
      "last_update_posted_date": "2024-02-07",
      "last_synced_at": "2026-10-01T19:23:16.228Z",
      "location_count": 3,
      "location_summary": "Los Angeles, California • Baltimore, Maryland • Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02750540"
    },
    {
      "nct_id": "NCT01227824",
      "title": "A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Infection, Human Immunodeficiency Virus I"
      ],
      "interventions": [
        {
          "name": "GSK1349572 (dolutegravir)",
          "type": "DRUG"
        },
        {
          "name": "raltegravir",
          "type": "DRUG"
        },
        {
          "name": "GSK1349572 Placebo",
          "type": "OTHER"
        },
        {
          "name": "ABC/3TC",
          "type": "OTHER"
        },
        {
          "name": "TDF/FTC",
          "type": "OTHER"
        },
        {
          "name": "raltegravir Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 828,
      "start_date": "2010-10-19",
      "completion_date": "2016-12-27",
      "has_results": true,
      "last_update_posted_date": "2018-10-09",
      "last_synced_at": "2026-10-01T19:23:16.228Z",
      "location_count": 20,
      "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Long Beach, California + 15 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01227824"
    }
  ]
}